Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing...
News Desk
Staff Writer
Published
Jun 14, 2026
Source
Fierce Biotech
Analytics
0 0 0

AI Insight:This news matters because it marks a significant milestone in the development of a potential new treatment for cancer patients.
Eli Lilly's up-to-$2.3 billion acquisition of Ajax Therapeutics is facing scrutiny, but the company has unveiled its first clinical data behind the deal, showing that its JAK inhibitor works effectively 'right out of the gate'. The data, presented at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrated the drug's ability to induce complete remission in patients with certain types of blood cancer. This promising result has the potential to revolutionize the treatment landscape for these patients, who often face limited options and poor prognosis. While the acquisition has been met with skepticism by some, the clinical data suggests that Lilly's bet on Ajax may be paying off, and the company's investment in the JAK inhibitor could yield significant returns in the form of improved patient outcomes and revenue growth.